Scilex (NASDAQ:SCLX) Given “Hold” Rating at D. Boral Capital

D. Boral Capital reaffirmed their hold rating on shares of Scilex (NASDAQ:SCLX) in a report issued on Friday morning,Benzinga reports.

Scilex Stock Performance

SCLX opened at $0.20 on Friday. The company has a market capitalization of $47.71 million, a P/E ratio of -0.24 and a beta of 1.04. The company has a 50-day moving average of $0.30 and a 200-day moving average of $0.53. Scilex has a 1-year low of $0.18 and a 1-year high of $2.30.

Scilex’s stock is going to reverse split on the morning of Tuesday, April 15th. The 1-35 reverse split was announced on Friday, April 11th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 14th.

Scilex (NASDAQ:SCLX) last released its earnings results on Friday, January 17th. The company reported ($0.18) EPS for the quarter. As a group, sell-side analysts expect that Scilex will post -0.57 earnings per share for the current fiscal year.

Institutional Trading of Scilex

Several institutional investors have recently added to or reduced their stakes in SCLX. RA Capital Management L.P. lifted its position in shares of Scilex by 296.7% in the 4th quarter. RA Capital Management L.P. now owns 1,036,218 shares of the company’s stock worth $442,000 after buying an additional 775,039 shares during the last quarter. Northern Trust Corp raised its stake in Scilex by 64.0% during the fourth quarter. Northern Trust Corp now owns 1,273,968 shares of the company’s stock worth $543,000 after acquiring an additional 497,182 shares during the period. Norges Bank acquired a new stake in Scilex during the fourth quarter worth about $204,000. Jane Street Group LLC lifted its holdings in Scilex by 965.8% in the fourth quarter. Jane Street Group LLC now owns 321,480 shares of the company’s stock worth $137,000 after acquiring an additional 291,316 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in Scilex by 28.7% in the fourth quarter. Janus Henderson Group PLC now owns 687,547 shares of the company’s stock valued at $293,000 after acquiring an additional 153,245 shares during the period. Institutional investors own 69.67% of the company’s stock.

Scilex Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.